HSBC SFH (France) launches a Consent Solicitation
HSBC SFH (France) (Paris:HSBAK) (a limited liability company (société anonyme) established under the laws of the Republic of France) (the “Issuer”) today announces the launch of a Consent Solicitation to the holders of the €1,250,000,000 2.00 per cent. Covered Bonds due 16 October 2023 (ISIN: FR0011470764) of which €1,250,000,000 are currently outstanding (the “2023 Covered Bonds”) and €1,000,000,000 0.500 per cent. Covered bonds due 17 April 2025 extendible as Floating Rate Covered Bonds up to 17 April 2026 (ISIN: FR0013329638) of which €1,000,000,000 are currently outstanding (the “2025 Covered Bonds” and, together with the 2023 Covered Bonds, the “Covered Bonds” and each a “Series”) issued by the Issuer.
The Issuer is seeking the consent of the holders of the Covered Bonds (the “Bondholders”) to approve the Resolutions all as more fully described in the Consent Solicitation Memorandum dated 25 November 2021 and which is available to holders of the Covered Bonds, notably, from the Centralisation Agent (upon request and free of charge). Capitalised terms are as defined in the Consent Solicitation Memorandum.
Purpose of the Consent Solicitation
The Covered Bonds have been issued by the Issuer and are currently legal, valid and binding obligations of the Issuer. 100.00 per cent. of the Issuer’s share capital is held directly or indirectly by HSBC Continental Europe (formerly known as HSBC France) (“HBCE”).
On 18 June 2021, HBCE signed a Memorandum of Understanding (“MoU”) with Promontoria MMB SAS, its subsidiaries Banque des Caraïbes SA and My Money Bank regarding the potential sale of its retail banking business in France which includes HBCE’s 100% ownership interest in the Issuer.
Promontoria MMB SAS, Banque des Caraïbes SA and My Money Bank are under the control, directly or indirectly, of funds and accounts managed or advised by Cerberus Capital Management L.P.
Further information can be found in the press release dated 18 June 2021 published on the websites of HBCE (https://www.hsbc.com/news-and-media/media-releases/2021/sale-of-retail-banking-business-in-france) and the Issuer (https://www.about.hsbc.fr/investor-relations/covered-bonds/-/media/france/en/investors-relations/releases/210618-release-potential-sale-of-hsbc-sfh-en.pdf).
On 25 November 2021, HBCE, Promontoria MMB SAS and Banque des Caraïbes SA entered into a Framework Agreement whereby HBCE would transfer, among other things, and subject to the satisfaction of certain conditions, its full ownership interest in the Issuer and most of its rights and obligations under the Programme Documents to which it is a party, including, notably, in its capacity as borrower, administrator, issuer calculation agent and cash collateral provider, to (i) Banque des Caraïbes SA and/or (ii) any other entity within My Money Group (the “Transfer”), as further detailed in the transaction update published by HBCE on its website (https://www.hsbc.fr/en-fr/actualites/) and in a press release published by Promontoria MMB SAS on its website (https://www.mymoneybank.com/en/news).
First Resolution in respect of the 2025 Covered Bonds / Second Resolution in respect of the 2023 Covered Bonds
The first Resolution of the 2025 Meeting and the second Resolution of the 2023 Meeting consist of the approval of the Transfer and all consequential amendments to the Programme Documents and to the Conditions.
Indeed, to achieve such Transfer, the Programme Documents will have to be amended. In particular, HBCE (formerly known as HSBC France), as the majority shareholder of the Issuer, has undertaken pursuant to a letter of undertaking in favour of the Bondholders, inter alia, (i) not to permit any amendments to the Programme Documents other than as expressly permitted or contemplated under the Programme Documents or without the prior Representative Consent and prior Rating Affirmation (in each case, as such capitalised terms are defined under the relevant Conditions), (ii) not to sell, transfer, lease out or otherwise dispose of, in one (1) or more transactions or series of transactions (whether or not related), whether voluntarily or involuntarily, the whole or any part of the shares of the Issuer it owns, (iii) to take any necessary steps, which are available to it as shareholder, to remain majority shareholder of the Issuer. In addition, HSBC Bank plc, acting through its Paris Branch, pursuant to the same letter of undertaking has undertaken in favour of the Bondholders, not to permit the Issuer to cease to be consolidated within the tax group formed under the régime d'intégration fiscale provided by Articles 223 A et seq. of the French Code général des impôts, with HSBC Bank plc, acting through its Paris Branch as head of that tax group, and not to amend the tax consolidation agreement (convention d'intégration fiscale) between HSBC Bank plc, acting through its Paris Branch and the Issuer without prior Rating Affirmation.
The Bondholders are therefore requested to waive any undertaking made by HBCE to their benefit in any such Programme Documents in the context of the Transfer including, for the avoidance of doubt, the undertakings in relation to any Rating Affirmation and/or Representative Consent. Further details are contained in the convening notices dated the date hereof and available, notably, on the Issuer’s website (https://www.about.hsbc.fr/fr-fr/investor-relations/covered-bonds and https://www.about.hsbc.fr/investor-relations/covered-bonds) and HBCE website (https://www.about.hsbc.fr/fr-fr/investor-relations and https://www.about.hsbc.fr/investor-relations).
First Resolution in respect of the 2023 Covered Bonds only
The first Resolution of the 2023 Meeting consists of the approval of the appointment of a new Representative and a new Alternative Representative (as such terms are defined in the 2023 Resolutions) following the resignation of BNP Paribas Securities Services and Mr. Frédéric Krantz, and the determination of their remuneration. As a consequence, Condition 12(b) (Representative) of the 2023 Conditions will be amended.
Second Resolution in respect of the 2025 Covered Bonds / Third Resolution in respect of the 2023 Covered Bonds
The second Resolution of 2025 Meeting and the third Resolution of 2023 Meeting are purely technical resolutions relating to filing of the documents relating to the Meeting of each Series.
Third Resolution in respect of the 2025 Covered Bonds / Fourth Resolution in respect of the 2023 Covered Bonds
The third Resolution of 2025 Meeting and the fourth Resolution of 2023 Meeting are purely technical resolutions granting capacities for formalities.
Consent Fees
Subject to all Resolutions being approved at the Meetings of each Series (whether held on first convocation or second convocation) (such interconditionality being waivable by the Issuer in its sole and absolute discretion), the Issuer will pay:
(i) in respect of the 2023 Meeting:
a. on the 2023 First Consent Fee Payment Date, an amount equal to 0.10 per cent. of the aggregate nominal amount of the 2023 Covered Bonds for which any 2023 Bondholder has validly cast its vote. The 2023 First Consent Fee will be paid by the Centralising Agent, on behalf of the Issuer, to the 2023 Bondholders holding the 2023 Covered Bonds on the date of the relevant 2023 Meeting and who have validly cast their votes; and
b. on the 2023 Second Consent Fee Payment Date, an amount equal to 0.05 per cent. of the aggregate nominal amount of the 2023 Covered Bonds held by each 2023 Bondholder only if the Transfer is completed prior to 16 October 2023 (being the maturity date of the 2023 Covered Bonds). The 2023 Second Consent Fee will be paid by the Paying Agent (in coordination with the Centralising Agent), on behalf of the Issuer, to all 2023 Bondholders holding the 2023 Covered Bonds at the 2023 Second Consent Fee Payment Date.
(ii) in respect of the 2025 Meeting:
a. on the 2025 First Consent Fee Payment Date, an amount equal to 0.20 per cent. of the aggregate nominal amount of the 2025 Covered Bonds for which any 2025 Bondholder has validly cast its vote. The 2025 First Consent Fee will be paid by the Centralising Agent, on behalf of the Issuer, to the 2025 Bondholders holding the 2025 Covered Bonds on the date of the relevant 2025 Meeting and who have validly cast their votes; and
b. on the 2025 Second Consent Fee Payment Date, an amount equal to 0.05 per cent. of the aggregate nominal amount of the 2025 Covered Bonds held by each 2025 Bondholder only if the Transfer is completed. The 2025 Second Consent Fee will be paid by the Paying Agent (in coordination with the Centralising Agent), on behalf of the Issuer, to all 2025 Bondholders holding the 2025 Covered Bonds at the 2025 Second Consent Fee Payment Date.
For the avoidance of doubt, a Bondholder will be considered to have validly cast its vote if it has voted “for”, “against” or “abstention” in respect of the relevant Resolutions submitted by the Issuer to the relevant Meeting, be it in person, by proxy or by correspondence.
Expected timetable
Announcement of the Consent Solicitation and publication of the 2023 Notice and of the 2025 Notice: |
|
|
Consent Solicitation Memorandum available at the registered office of the Issuer, at the office of the Centralising Agent (copies of which are obtainable, upon request, free of charge) and at the specified office of the Paying Agent: |
25 November 2021 |
|
Publication of the 2023 Notice and of the 2025 Notice through Euroclear France and on the websites of the Issuer (https://www.about.hsbc.fr/fr-fr/investor-relations/covered-bonds and https://www.about.hsbc.fr/investor-relations/covered-bonds) and of HBCE (https://www.about.hsbc.fr/fr-fr/investor-relations and https://www.about.hsbc.fr/investor-relations): |
25 November 2021 |
|
Voting Documents Deadline: |
|
|
Latest time and date for receipt by the Centralising Agent of Voting Documents whether by post or by email: |
7 December 2021 at 23.59 (Paris time) (final reception date) |
|
Account Holder Certificates Deadline: Deadline to have the right to participate to the 2023 Meeting:
Deadline to have the right to participate to the 2025 Meeting: |
10 December 2021 at 10.00 a.m. (Paris time) 10 December 2021 at 11.00 a.m. (Paris time) |
|
Time and date of the 2023 Meeting on first convocation: |
10.00 a.m. (Paris time) on 10 December 2021 |
|
Time and date of the 2025 Meeting on first convocation: |
11.00 a.m. (Paris time) on 10 December 2021 |
|
Publication of the results of the 2023 Meeting and of the 2025 Meeting (if quorate): |
|
|
Publication of the results notice notably through Euroclear France and on the websites of the Issuer (https://www.about.hsbc.fr/fr-fr/investor-relations/covered-bonds and https://www.about.hsbc.fr/investor-relations/covered-bonds) and of HBCE (https://www.about.hsbc.fr/fr-fr/investor-relations and https://www.about.hsbc.fr/investor-relations): |
As soon as reasonably practicable after the 2023 Meeting and the 2025 Meeting held on first convocation |
If the quorum is not met at the 2023 Meeting held on first convocation, or at the 2025 Meeting held on first convocation, notice for the second convocation: |
|
|
Publication of the convening notice through Euroclear France and on the websites of the Issuer (https://www.about.hsbc.fr/fr-fr/investor-relations/covered-bonds and https://www.about.hsbc.fr/investor-relations/covered-bonds) and of HBCE (https://www.about.hsbc.fr/fr-fr/investor-relations and https://www.about.hsbc.fr/investor-relations): |
10 December 20211 |
|
Voting Documents Deadline in respect of the 2023 Meeting and the 2025 Meeting held on second convocation: |
|
|
Latest time and date for receipt by the Centralising Agent of Voting Documents whether by post or by email: |
18 December 2021 at 23.59 (Paris time) (final reception date)2 |
|
Account Holder Certificates Deadline: Deadline to have the right to participate to the 2023 Meeting:
|
21 December 2021 at 10.00 a.m. (Paris time)3 21 December 2021 at 11.00 a.m. (Paris time)4 |
|
2023 Meeting on second convocation and 2025 Meeting on second convocation (if applicable): |
|
|
Time and date of the 2023 Meeting on second convocation: |
10.00 a.m. (Paris time) on 21 December 20215 |
|
Time and date of the 2025 Meeting on second convocation: |
11.00 a.m. (Paris time) on 21 December 20216 |
|
Publication of the results of the 2023 Meeting and of the 2025 Meeting: |
|
|
Publication of the results notice notably through Euroclear France and on the websites of the Issuer (https://www.about.hsbc.fr/fr-fr/investor-relations/covered-bonds and https://www.about.hsbc.fr/investor-relations/covered-bonds) and of HBCE (https://www.about.hsbc.fr/fr-fr/investor-relations and https://www.about.hsbc.fr/investor-relations): |
As soon as reasonably practicable after the 2023 Meeting and the 2025 Meeting held on second convocation |
|
Payment of the 2023 Consent Fee: |
|
|
Payment of the 2023 First Consent Fee to any 2023 Bondholder who has validly cast its vote if all Resolutions are approved at the Meetings of each Series (whether held on first convocation or on second convocation) (such interconditionality being waivable by the Issuer in its sole and absolute discretion), otherwise no payment. The 2023 First Consent Fee will be paid by the Centralising Agent, on behalf of the Issuer, to the 2023 Bondholders holding the 2023 Covered Bonds on the date of the relevant 2023 Meeting and who have validly cast their votes: |
At the latest 3 Business Days following the date of the latest Meeting of any Series (i.e. 10 December 2021, on first convocation or, if the quorum is not met with respect to any Series, 21 December 2021, on second convocation) |
|
Payment of the 2025 Consent Fee: |
|
|
Payment of the 2025 First Consent Fee to any 2025 Bondholder who has validly cast its vote if all Resolutions are approved at the Meetings of each Series (whether held on first convocation or on second convocation) (such interconditionality being waivable by the Issuer in its sole and absolute discretion), otherwise no payment. The 2025 First Consent Fee will be paid by the Centralising Agent, on behalf of the Issuer, to the 2025 Bondholders holding the 2025 Covered Bonds on the date of the relevant 2025 Meeting and who have validly cast their votes: |
At the latest 3 Business Days following the date of the latest Meeting of any Series (i.e. 10 December 2021, on first convocation or, if the quorum is not met with respect to any Series, 21 December 2021, on second convocation) |
|
Notice announcing the Completion of the Transfer: |
As soon as practicable following the Completion of the Transfer |
|
Payment of the 2023 Second Consent Fee if (i) all Resolutions are approved at the Meetings of each Series (whether held on first convocation or on second convocation) (such interconditionality being waivable by the Issuer in its sole and absolute discretion) and (ii) the Transfer is completed prior to 16 October 2023 (being the maturity date of the 2023 Covered Bonds), otherwise no payment. The 2023 Second Consent Fee will be paid by the Paying Agent (in coordination with the Centralising Agent), on behalf of the Issuer, to all 2023 Bondholders holding the 2023 Covered Bonds at the 2023 Second Consent Fee Payment Date: |
At the latest 5 Business Days following the Completion of the Transfer |
|
Payment of the 2025 Second Consent Fee if (i) all Resolutions are approved at the Meetings of each Series (whether held on first convocation or on second convocation) (such interconditionality being waivable by the Issuer in its sole and absolute discretion) and (ii) the Transfer is completed, otherwise no payment. The 2025 Second Consent Fee will be paid by the Paying Agent (in coordination with the Centralising Agent), on behalf of the Issuer, to all 2025 Bondholders holding the 2025 Covered Bonds at the 2025 Second Consent Fee Payment Date: |
At the latest 5 Business Days following the Completion of the Transfer |
1 Subject to adjustment as may be specified in the convening notice(s) convening the 2023 Meeting or the 2025 Meeting on second convocation.
2 Subject to adjustment as may be specified in the convening notice(s) convening the 2023 Meeting or the 2025 Meeting on second convocation.
3 Subject to adjustment as may be specified in the convening notice convening the 2023 Meeting on second convocation.
4 Subject to adjustment as may be specified in the convening notice convening the 2025 Meeting on second convocation.
5 Subject to adjustment as may be specified in the convening notice convening the 2023 Meeting on second convocation.
6 Subject to adjustment as may be specified in the convening notice convening the 2025 Meeting on second convocation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125005972/en/
Contact information
For general assistance and queries relating to the Consent Solicitation please contact the Solicitation Agents, the Issuer or the Centralisation Agent at:
Solicitation Agents:
Crédit Agricole Corporate and Investment Bank, Attention: Liability Management Group, Tel: +44 20 7214 5733, Email: liability.management@cacib.com
HSBC Continental Europe, Attention: Liability Management, Tel: +44 20 7992 6237, Email: LM_EMEA@hsbc.com
Issuer:
HSBC SFH (France), Attention: Arnaud de Champfleur, Tel: +33 1 40 70 34 89, Email: hsbcsfh@hsbc.fr
Centralisation Agent:
CACEIS Corporate Trust, Attention: Service Assemblées Générales, Tel: +33 1 57 78 34 44 , Email: ct-assemblees@caceis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CORRECTING and REPLACING PHOTO Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 21:23:00 EEST | Press release
Please replace the photo with the accompanying corrected photo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. The release reads: DECODE THE FUTURE OF AI AND CUSTOMER EXPERIENCE AT ELEVATE'25 DIGITAL INNOVATION SUMMIT With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. Taking place on October 15, 2025, at the i
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release
Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release
AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by
illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release
illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom